RESMED INC 10-Q

Item 2 Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities Purchases of equity securities. On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. We are authorized to continue repurchasing shares through June 30, 2024, provided that the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program. We suspended our share repurchase program in fiscal year 2019. As a result, we did not repurchase any shares during the three months ended September 30, 2023. However, we recently announced in October 2023 that our board of directors has elected to reactivate and resume share repurchases pursuant to the share repurchase program as the circumstances allow. Since approval of the share repurchase program in 2014 through September 30, 2023, we have repurchased a total of 7.1 million shares under this repurchase program for an aggregate of $413 million. At September 30, 2023, 12.9 million additional shares of common stock can be repurchased under the approved share repurchase program. Item 3 Defaults Upon Senior Securities None Item 4 Mine Safety Disclosures None